More topics

Limited coverage criteria – ixekizumab

Last updated on March 18, 2025

 

Return to Special Authority drug list 

Generic name

ixekizumab

Strength & form

80 mg/1 mL solution for subcutaneous injection in a pre-filled syringe or pre-filled auto-injector

Special Authority criteria

Approval period

For the treatment of moderate to severe plaque psoriasis, according to criteria detailed in HLTH 5380, when a Special Authority request is submitted by a dermatologist

First approval: 12 weeks

Renewal: 1 year

For the treatment of moderate to severe psoriatic arthritis, according to criteria detailed in HLTH 5360 (Initial/Switch) or HLTH 5361 (renewal), when a Special Authority is submitted by a rheumatologist

First approval: 1 year

Renewal: 1 year

Practitioner exemptions

  • No practitioner exemptions

Special notes

  • PharmaCare covers a maximum of 28 days per fill for ixekizumab

Special Authority request form(s)